AbbVie的Q2收入缺失估计数,但收入增加;内幕人士出售股票,股票以231.90美元的目标关闭,为229.19美元。 AbbVie's Q2 earnings missed estimates, but revenue rose; insiders sold shares, and the stock closed at $229.19 with a $231.90 target.

Private Wealth Asset Management LLC 和 BankPlus Trust Department 在第二季度增持了艾伯维股份，而执行副总裁 Azita Saleki-Gerhardt 和 Nicholas Donoghoe 在 8 月份总共出售了 55,665 股股票，净赚超过 1100 万美元。 Private Wealth Asset Management LLC and BankPlus Trust Department increased their AbbVie stakes in Q2, while executive vice presidents Azita Saleki-Gerhardt and Nicholas Donoghoe sold a combined 55,665 shares in August, netting over $11 million. AbbVie报告,Q2收入为每股2.97美元,低于3.24美元的估计数,尽管收入增长了6.6%,达到15.42亿美元。 AbbVie reported Q2 earnings of $2.97 per share, below the $3.24 estimate, though revenue rose 6.6% to $15.42 billion. 股票以229.19美元关闭,市场上限为404.88亿美元,前期P/E为109.14美元。 The stock closed at $229.19 with a market cap of $404.88 billion and a forward P/E of 109.14. 分析师保持“机动购买”评级为231.90美元,目标为231.90美元。 Analysts maintain a "Moderate Buy" rating with a $231.90 target. 该公司的股息收益率为2.9%,退税日期为2025年10月15日。 The company’s dividend yield is 2.9%, with an ex-dividend date of October 15, 2025.